These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2676000)

  • 1. A randomized controlled study of (2"R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan.
    Tominaga T; Abe O; Enomoto K; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y
    Biomed Pharmacother; 1989; 43(4):271-8. PubMed ID: 2676000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Abe O; Tominaga T; Enomoto K; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y; Tanaka T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2160-8. PubMed ID: 3717960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan].
    Enomoto K; Tominaga T; Abe R; Iino Y; Koyama H; Nomura Y; Abe O; Nakazato H
    Gan To Kagaku Ryoho; 1996 Jun; 23(7):871-80. PubMed ID: 8678535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.
    ; Ambrosini G; Balli M; Garusi G; Demicheli R; Jirillo A; Bonciarelli G; Bruscagnin G; Fila G; Bumma C; Lacroix F; Buzzi F; Di Costanzo F; Padalino D; Brugia M; Calabresi F; Natali M; Cartei G; Chiesa G; Blasina B; Ciambellotti E; Moro G; D'Aquino S; Altavilla G; Adamo V; De Maria D; Falchi AM; Bertoncelli P; Farris A; Fiorentino M; Fornasiero A; Fosser V; Daniele O; Foggi CM; Speranza GB; Sartori S; Camilluzzi E; Gallo L; Poggio R; Secondo V; Gambi A; Grignani F; Capodicasa E; Lopez M; Papaldo P; Di Lauro L; Vici P; Marenco G; Folco U; Bonanni F; Marsilio P; Palazzotto G; Di Carlo A; Cusimano MP; Pastorino G; Puccetti C; Giusto M; Rausa L; Gebbia N; Palmeri S; D'Alessandro N; Saccani F; Becchi G; Schieppati G; Spinelli I; Tagliagambe A; Tonato M; Minotti V; Ardia A; Viaro D; De Micheli P; Zingali G; Sacchetti G; Intini C
    J Clin Oncol; 1988 Jun; 6(6):976-82. PubMed ID: 2897433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
    Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
    Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
    Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Taguchi T; Sakai K; Terasawa T; Wada H
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
    Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
    Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer. The Japan Toremifene Cooperative Study Group.
    Tominaga T; Nomura Y; Uchino J; Hirata K; Kimura M; Yoshida M; Aoyama H; Kinoshita H; Koyama H; Monden Y; Takashima S; Ogawa M
    Jpn J Clin Oncol; 1998 Apr; 28(4):250-4. PubMed ID: 9657010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
    Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
    Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic chemotherapy of mammary carcinoma: plasma and tissue concentrations of 5-fluorouracil and adriamycin, and result of CAF and CMF therapy of breast cancer].
    Murayama Y; Nagashima M
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):415-9. PubMed ID: 6546655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Kolarić K; Vukas D; Potrebica V
    Tumori; 1989 Apr; 75(2):132-6. PubMed ID: 2741218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
    Tashiro K; Machida T; Masuda F; Ohishi Y
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S43-6. PubMed ID: 6640834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of pirarubicin for breast cancer in Japan. Clinical Study Group of THP for Breast Cancer in Japan.
    Enomoto K; Abe O; Tominaga T; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y
    Am J Clin Oncol; 1990; 13 Suppl 1():S48-53. PubMed ID: 2291458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
    Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.